FDA Targets Ineffective Decongestant for Market Removal
TL;DR Summary
The FDA has proposed removing oral phenylephrine, a common ingredient in over-the-counter decongestants like Sudafed PE and DayQuil, from the market due to evidence of ineffectiveness. This proposal initiates a six-month public comment period before a final decision is made. While CVS has already stopped selling phenylephrine products, other pharmacies continue to stock them. The FDA's move follows several studies and an advisory committee's conclusion that phenylephrine is ineffective at typical oral dosages. The proposal does not affect phenylephrine used in nasal sprays.
- FDA moves to pull popular decongestant from shelves amid effectiveness concerns CNN
- FDA proposes ending use of decongestant found in many cold, allergy medicines CNBC
- FDA to pull common but ineffective cold medicine from market CBS News
- FDA proposes removing ineffective decongestant found in most cold medicine The Hill
- Better Breathing Through Bureaucracy: The FDA’s Half-Century Phenylephrine Saga Cato Institute
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
81%
441 → 83 words
Want the full story? Read the original article
Read on CNN